Kenvue Inc. (NYSE:KVUE) Shares Sold by Beech Hill Advisors Inc.

Beech Hill Advisors Inc. decreased its holdings in shares of Kenvue Inc. (NYSE:KVUE) by 8.9% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 108,320 shares of the company’s stock after selling 10,644 shares during the quarter. Beech Hill Advisors Inc.’s holdings in Kenvue were worth $2,332,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in KVUE. Clearstead Advisors LLC acquired a new position in Kenvue in the 3rd quarter worth $25,000. AdvisorNet Financial Inc acquired a new position in Kenvue in the 3rd quarter worth $28,000. Global Retirement Partners LLC acquired a new position in Kenvue in the 3rd quarter worth $28,000. Venturi Wealth Management LLC acquired a new position in Kenvue in the 3rd quarter worth $28,000. Finally, EverSource Wealth Advisors LLC acquired a new position in Kenvue in the 3rd quarter worth $28,000. Institutional investors and hedge funds own 11.33% of the company’s stock.

Kenvue Price Performance

NYSE KVUE traded down $0.14 on Monday, hitting $20.20. The stock had a trading volume of 18,790,544 shares, compared to its average volume of 17,984,738. Kenvue Inc. has a one year low of $17.82 and a one year high of $27.80. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.12 and a quick ratio of 0.78. The company’s 50-day moving average is $20.12 and its two-hundred day moving average is $20.31.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 8th. The company reported $0.31 EPS for the quarter, topping the consensus estimate of $0.28 by $0.03. Kenvue had a net margin of 9.87% and a return on equity of 15.62%. The firm had revenue of $3.67 billion during the quarter, compared to analysts’ expectations of $3.78 billion. The business’s revenue for the quarter was down 2.7% on a year-over-year basis. On average, equities analysts predict that Kenvue Inc. will post 1.17 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, February 28th. Shareholders of record on Wednesday, February 14th were given a $0.20 dividend. This represents a $0.80 annualized dividend and a yield of 3.96%. The ex-dividend date was Tuesday, February 13th.

Analysts Set New Price Targets

A number of brokerages have commented on KVUE. The Goldman Sachs Group began coverage on shares of Kenvue in a report on Friday, March 1st. They issued a “neutral” rating and a $20.00 price objective on the stock. Royal Bank of Canada cut their target price on shares of Kenvue from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Friday, February 9th. JPMorgan Chase & Co. cut their target price on shares of Kenvue from $25.00 to $24.00 and set an “overweight” rating on the stock in a research note on Friday, February 9th. Finally, UBS Group upped their target price on shares of Kenvue from $20.00 to $23.00 and gave the company a “neutral” rating in a research note on Tuesday, December 19th. Seven analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. Based on data from MarketBeat, Kenvue has an average rating of “Moderate Buy” and a consensus price target of $25.42.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, and other products under the Tylenol, Nicorette, and Zyrtec brands.